Stay updated with breaking news from Arix Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Arix Bioscience PLC - London-based transatlantic venture capital company focused on investing in biotechnology companies that are advancing in life science - Reports its estimated net asset value... | May 12, 2023
Acacia Research Corporation today reported financial results for the three months ended March 31, 2023. Key Business Highlights Executed a Rights Offering , raising $79.1 million in net... | May 11, 2023
The following is a round-up of share dealings by London-listed company directors and managers announced this week and not separately reported by Alliance News: ---------- Ferro-Alloy Resources Ltd -... | May 5, 2023
New and current investors of Evommune have recently completed a $50 million Series B financing toward three of the company’s pipeline programs targeting prevalent inflammatory disease, according to a company press release. The $50 million Series B financing was led by Arix Bioscience, a new investor in Evommune, EQT Life Sciences and SymBiosis along with financial contributions from
Arix Co-leads $50 Million Series B Financing for New Portfolio Company EvommuneLONDON, 27 April 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that the Series B fi...